• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Chronic Disease

START intervention for dementia caregivers linked to reduction of depression symptoms

byMelissa McCoyandXiaozhou Liu
November 21, 2014
in Chronic Disease, Neurology, Psychiatry
Reading Time: 3 mins read
START intervention for dementia caregivers linked to reduction of depression symptoms
Share on FacebookShare on Twitter

1. The STrAtegies for RelaTives (START) intervention provided to caregivers of dementia patients was linked to a seven-fold reduction in clinically significant depression than compared to receiving treatment as usual.

2. The START intervention was demonstrated to be cost effective as defined by National Institute for Health and Care thresholds for both caregivers and patients as costs did not significantly differ between groups receiving the intervention and those receiving treatment as usual.

Evidence Rating Level: 1 (Excellent)      

Study Rundown: Two-thirds of dementia patients live at home and are cared for by family members. Caregivers of dementia patients frequently develop anxiety and depression, which can lead to breakdown in quality caregiving. The START intervention study aimed to assess the clinical effectiveness (reduction in depression and anxiety symptoms) and cost effectiveness of a psychological intervention for caregivers. Caregivers were randomly assigned to either the experimental START group, a manual-based coping intervention, or the control group who received treatment as usual (TAU). The caregivers who participated in START were significantly less likely to have depression and anxiety symptoms, and the intervention was found to be cost-effective for both caregivers and patients. Policymakers are urged to consider this effective approach for the prevention of depression in caregivers as well as the continuance of quality care for people with dementia. Sociodemographic and clinical characteristics of participants were heterogeneous, lending strength to this study. Though the difference in cost effectiveness between TAU and START did not significantly differ, the study was limited in that the trial was not powered for the economic evaluation.

This study was funded by the National Institute for Health Research Health Technology Assessment program.

Click to read the study, published today in The Lancet Psychiatry

RELATED REPORTS

The Scan by 2 Minute Medicine®: Sugary drinks track with higher depression risk while coffee shows the opposite, US measles cases reach their highest level in decades, peptide injections fuel the next wellness craze, and most routine blood tests do not require prolonged fasting

Earlier menopause is associated with faster cognitive decline and greater late-life brain changes

Artificial intelligence (AI) chatbot reduced depression, anxiety, and eating disorder risk symptoms

Relevant Reading: Clinical effectiveness of a manual based coping strategy programme (START, STrAtegies for RelaTives) in promoting the mental health of carers of family members with dementia: pragmatic randomised controlled trial

In-Depth [randomized controlled trial]: This study assessed the long-term clinical effectiveness and cost effectiveness of the psychological intervention START (STrAtegies for RelaTives) in self-identified caregivers of dementia patients who provided support at least once per week. START consists of 8 sessions of manual-based, individual coping interventions. Primary long-term outcome at 2 years after randomization for clinical effectiveness was measured via affective symptoms (Hospital Anxiety and Depression Scale total score [HADS-T]). Primary outcome for cost effectiveness was measured via National Institute for Health and Care (NICE) thresholds.

260 British caregivers were enrolled in the study and were randomized (2:1) with 173 allotted to the START group and 87 to the TAU group. Of the 260 participants, 209 (80%) were included in the final analysis (140 START, 69 TAU). Caregivers met 8 times with non-clinically trained psychology graduates who had been trained to deliver the START intervention. At 2 years, the START group reported significantly better HADS-T scores than the TAU group (mean difference –2.58 points, 95% CI –4.26 to –0.90; p=0.003). Cost effectiveness measures demonstrated that START is cost effective for both caregivers and patients (67% probability of cost-effectiveness at the £20,000 per QALY willingness-to-pay threshold, and 70% at the £30,000 threshold).

More from this author: Mechanical CPR provides no benefit over manual CPR [PARAMEDIC trial], Group B streptococcus infections on the rise despite prevention guidelines, Transplanted stem cells help restore sight in age-related macular degeneration, Quality of life measures similar between teens with and without cerebral palsy, Long working hours linked with diabetes in low socioeconomic groups

Image: PD

©2014 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. No article should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2 Minute Medicine, Inc.

Tags: dementiadepression
Previous Post

HPV triage is optimal management for ASCUS [Classics Series]

Next Post

Shear-wave elastography may improve prostate cancer detection

RelatedReports

The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Sugary drinks track with higher depression risk while coffee shows the opposite, US measles cases reach their highest level in decades, peptide injections fuel the next wellness craze, and most routine blood tests do not require prolonged fasting

October 6, 2026
Longevity

Earlier menopause is associated with faster cognitive decline and greater late-life brain changes

October 5, 2026
Artificial Intelligence

Artificial intelligence (AI) chatbot reduced depression, anxiety, and eating disorder risk symptoms

September 11, 2026
Quick Take: Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine
Chronic Disease

Dementia diagnosis underreporting is common and associated with reduced care engagement

August 29, 2026
Next Post
Sunitinib showed no change in overall survival for metastatic prostate cancer

Shear-wave elastography may improve prostate cancer detection

Type II diabetes associated with decreased survival in pancreatic cancer

Type II diabetes associated with decreased survival in pancreatic cancer

Assisted conception not associated with increased pediatric cancer risk

Culture characteristics not associated with birthweight from assisted reproduction

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Rimegepant (Nurtec ODT) may be an effective alternative to triptans for symptom relief in migraines
  • Dexmedetomidine (Precedex) may offer similar analgesic efficacy as remifentanil (Ultiva) with fewer adverse effects in adults undergoing sleeve gastrectomy
  • The Scan by 2 Minute Medicine®: Sugary drinks track with higher depression risk while coffee shows the opposite, US measles cases reach their highest level in decades, peptide injections fuel the next wellness craze, and most routine blood tests do not require prolonged fasting
License Content
Terms of Use | Disclaimer
Cookie Policy
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.